KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gilead Sciences (GILD) Receivables - Other (2018 - 2025)

Historic Receivables - Other for Gilead Sciences (GILD) over the last 8 years, with Q3 2025 value amounting to $695.0 million.

  • Gilead Sciences' Receivables - Other rose 27771.74% to $695.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $695.0 million, marking a year-over-year increase of 27771.74%. This contributed to the annual value of $277.0 million for FY2024, which is 13675.21% up from last year.
  • Latest data reveals that Gilead Sciences reported Receivables - Other of $695.0 million as of Q3 2025, which was up 27771.74% from $305.0 million recorded in Q2 2025.
  • Gilead Sciences' Receivables - Other's 5-year high stood at $695.0 million during Q3 2025, with a 5-year trough of $117.0 million in Q4 2023.
  • Its 5-year average for Receivables - Other is $209.8 million, with a median of $167.0 million in 2021.
  • As far as peak fluctuations go, Gilead Sciences' Receivables - Other plummeted by 3157.89% in 2023, and later skyrocketed by 27771.74% in 2025.
  • Over the past 5 years, Gilead Sciences' Receivables - Other (Quarter) stood at $174.0 million in 2021, then decreased by 1.72% to $171.0 million in 2022, then plummeted by 31.58% to $117.0 million in 2023, then surged by 136.75% to $277.0 million in 2024, then skyrocketed by 150.9% to $695.0 million in 2025.
  • Its Receivables - Other was $695.0 million in Q3 2025, compared to $305.0 million in Q2 2025 and $304.0 million in Q1 2025.